Inotuzumab ozogamicin

Drug Profile

Inotuzumab ozogamicin

Alternative Names: CMC-544; PF-5208773; WAY-207294

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator UCB
  • Developer National Cancer Institute (USA); Pfizer; SWOG; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytostatic antibiotics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action CD22 antigen inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acute lymphoblastic leukaemia
  • Phase I/II Chronic myeloid leukaemia
  • Phase I Leukaemia
  • Discontinued Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Dec 2016 Efficacy and adverse events data from a phase I/II trial in Acute lymphoblastic leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 30 Nov 2016 National Cancer Institute and Children's Oncology Group plan a phase II trial for Acute lymphoblastic leukaemia (Second-line therapy or greater, In children, In infants, In adolescents, In adults) in USA (IV) (NCT02981628)
  • 12 Jun 2016 Efficacy and adverse events data from the phase III INO-VATE ALL trial in Acute lymphoblastic leukaemia (Second-line therapy or greater) presented at the 21st Congress of the European Haematology Association (EHA-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top